Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence

Wed, 01/19/2011 - 10:33am

CAMBRIDGE, Mass., Jan. 19, 2011 /PRNewswire/ -- Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis (the spread of cancer cells to secondary locations). A cornerstone of Pervasis' oncology program, the company has entered into an exclusive patent license agreement with the Massachusetts Institute of Technology (MIT) for all discovery and development activities associated with cellular implants for cancer diagnosis, prognosis and treatment. In addition, supportive evidence from multiple preclinical studies demonstrates the powerful anti-angiogenic, anti-proliferative and anti-inflammatory properties of this endothelial cell-based approach in the presence of various solid tumor cancers, such as brain, lung, breast and prostate.

Pervasis, a clinical stage company based in Cambridge, Mass., is focused on developing breakthrough cell-based therapies that harness the healing power of the endothelium, the thin layer of cells that lines the interior surface of every blood vessel in the body. The company's other areas of clinical investigation include improving outcomes following common vascular surgical and interventional procedures, such as hemodialysis access, angioplasties, stents and peripheral and coronary bypass grafts -- the failures of which result in serious complications and a significant increase in medical costs.

"We are very excited to expand our focus to include the critical area of oncology," stated Frederic Chereau, president and chief executive officer of Pervasis. "We already have amassed a significant amount of data demonstrating the safety and efficacy of utilizing our novel cell-based approach to improve outcom





Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.